The U.S. Securities and Exchange Commission and the U.S. Food and Drug Administration entered into a memorandum of understanding to strengthen cooperation on regulatory and enforcement matters involving financial market integrity and public health. The framework establishes protocols for exchanging information relevant to both agencies, including information connected to FDA-related disclosures by public companies. The arrangement is intended to improve market oversight, compliance and transparency across the life sciences sector. It will remain in effect for three years and may be extended or modified by mutual written consent.